Pharma News, 2024

Leqembi is intended for patients with mild cognitive impairment or at the mild dementia stage of the disease. Leqembi is the first treatment proven to slow the progression of AD.

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Trials assessed the drug’s safety and efficacy, with one Phase I/IIa trial conducted in the country and an external Phase I trial. AusperBio Therapeutics and Ausper Biopharma have gained breakthroug...

A. baumannii is most commonly responsible for urinary tract infections, ventilator-associated pneumonia, central line-associated bloodstream infections, persistent wound infections and meningitis

Ivermectin is an attractive cancer drug candidate as it’s inexpensive and already clinically approved, albeit for parasitic infections. Some preclinical studies have indeed found promising result...

IGC Pharma, Inc. today announced preclinical data demonstrating TGR-63’s potential as an effective treatment for Alzheimer’s disease. Analysis of the partition coefficient and mass spectrometry of...

The study results can help advance the treatment of traumatic brain injury (TBI) for both military service members and civilians.

Company has completed the required preclinical studies and will seek regulatory approval to dose volunteers in Belgium by the end of the year.

Eli Lilly has signed a definitive agreement to acquire Morphic Holding for $3.2bn, expanding its inflammatory bowel disease (IBD) portfolio. Morphic’s lead asset MORF-057 is being investigat...

GSK and Medicines for Malaria Venture (MMV) have announced the launch of a new single-dose medicine, tafenoquine, to prevent the relapse of Plasmodium vivax (P. vivax) malaria in malar...

A New Jersey Congressman says America is far behind Europe when it comes to putting the best sunscreen products on store shelves. Democrat Josh Gottheimer is calling on the feder...

Ascentage Pharma has obtained approval for its new BCR-ABL1 [a gene sequence found in certain forms of leukaemia] tyrosine kinase inhibitor (TKI), olverembatinib, from the Pharmaceutical Admin...